Abstract 267P
Background
Homologous recombination deficiency (HRD) score serves as a promising biomarker to identify patients who are eligible for treatment with PARP inhibitor (PARPi). Previous studies have suggested a 3-biomarker Genomic Instability Score (GIS) threshold of ≥42 is a valid biomarker to predict response to PARPi in patients with ovarian cancer. However, the GIS threshold for prostate cancer (PCa) is still lacking. Here, we conducted an exploratory analysis to investigate an appropriate GIS score and to evaluate its ability to predict response to PARPi in prostate cancer patients.
Methods
A total of 225 patients with PCa were included in this study. Tumor tissue specimens were collected for targeted next-generation sequencing for homologous recombination repair (HRR) genes and promoter methylation analysis. GIS score was calculated based on over 50,000 single-nucleotide polymorphisms (SNP) distributed across the human genome, incorporating three SNP-based assays: loss of heterozygosity, telomeric allelic imbalance, and large-scale state transition. The HRD score threshold was set at the 5th percentile of the GIS scores in our cohort of known BRCA1/2-deficient tumors which is the method used to define the HRD threshold in breast and ovarian cancer.
Results
In our cohort, 22 patients (9.78%) had BRCA1/2 mutations or BRCA1/2 promoter methylation, with additional 32 patients (14.22%) carrying mutations in HRR genes. The median HRD score was 2 (ranged from 0 to 78) in total cohort which is much lower than that of in breast and ovarian cancer. The 5th percentile of HRD scores was 9 in the BRCA1/2-deficient cohort and consequently high HRD was defined as HRD scores >9. In the 12 patients who received PARPi in our cohort, 8 patients with a high HRD score achieved a disease control rate of 83.3%. In addition, 4 patients with a low HRD score but with mutations in HRR genes other than BRCA1/2 achieved a disease control rate of 25.0%.
Conclusions
HRD positive, defined as GIS score >9, may be an appropriate threshold to predict the likelihood of response to PARPi in prostate cancer. Prospective, and large sample clinical trials will be needed to confirm our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. Wang.
Funding
China Anti-Cancer Association-Hengrui PARP Inhibitor Cancer Research Fund (Phase I).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract